YU1203A - Treatment and prevention of cardiac insulin resistance associated conditions - Google Patents

Treatment and prevention of cardiac insulin resistance associated conditions

Info

Publication number
YU1203A
YU1203A YU1203A YUP1203A YU1203A YU 1203 A YU1203 A YU 1203A YU 1203 A YU1203 A YU 1203A YU P1203 A YUP1203 A YU P1203A YU 1203 A YU1203 A YU 1203A
Authority
YU
Yugoslavia
Prior art keywords
insulin resistance
treatment
cardiac insulin
prevention
cardiac
Prior art date
Application number
YU1203A
Other languages
Serbo-Croatian (sh)
Inventor
Ameet Nathwani
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of YU1203A publication Critical patent/YU1203A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for the treatment or prophylaxis of cardiac insulin resistance or conditions associated with cardiac insulin resistance, in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of PPARy agonist, such as Compound (I), or a pharmaceutically acceptable derivative thereof. Conditions associated with cardiac insulin resistance are: microvascular angina, atherosclerosis and congestive heart failure. Compounds include rosiglitazone, troglitazone, englitazone and pioglitazone.
YU1203A 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions YU1203A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/002347 WO2001095906A1 (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Publications (1)

Publication Number Publication Date
YU1203A true YU1203A (en) 2006-05-25

Family

ID=9884792

Family Applications (1)

Application Number Title Priority Date Filing Date
YU1203A YU1203A (en) 2000-06-16 2000-06-16 Treatment and prevention of cardiac insulin resistance associated conditions

Country Status (15)

Country Link
EP (1) EP1292301A1 (en)
JP (1) JP2004503499A (en)
CN (1) CN1592620A (en)
AP (1) AP2002002688A0 (en)
BG (1) BG107384A (en)
BR (1) BR0017254A (en)
CA (1) CA2436116A1 (en)
DZ (1) DZ3389A1 (en)
EA (1) EA200300028A1 (en)
HU (1) HUP0301103A2 (en)
IL (1) IL153452A0 (en)
MX (1) MXPA02012619A (en)
NO (1) NO20026000L (en)
WO (1) WO2001095906A1 (en)
YU (1) YU1203A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
MA26662A1 (en) * 1998-07-21 2004-12-20 Smithkline Beecham Plc THIAZOLIDINEDIONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE

Also Published As

Publication number Publication date
NO20026000D0 (en) 2002-12-13
IL153452A0 (en) 2003-07-06
JP2004503499A (en) 2004-02-05
BR0017254A (en) 2004-01-06
CN1592620A (en) 2005-03-09
WO2001095906A1 (en) 2001-12-20
BG107384A (en) 2003-09-30
NO20026000L (en) 2003-02-11
AP2002002688A0 (en) 2002-12-31
EP1292301A1 (en) 2003-03-19
EA200300028A1 (en) 2003-04-24
HUP0301103A2 (en) 2003-08-28
CA2436116A1 (en) 2001-12-20
MXPA02012619A (en) 2003-04-10
DZ3389A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
Al Zuhair et al. Pumpkin-seed oil modulates the effect of felodipine and captopril in spontaneously hypertensive rats
NL300282I1 (en) New exendin agonist formulations and method for administration thereof.
WO2006107860A3 (en) Dihydropyridine compounds and compositions for headaches
AR093609A2 (en) AMORFO COMPOUND OF BENZIMIDAZOL, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND METHOD TO TREAT OR PREVENT GASTRIC ULCERA
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2008142627A3 (en) Multilayered modified release formulation comprising amoxicillin and clavulanate
NO20061818L (en) Method of Inhibiting Remnant Lipoprotein Production
TN2011000228A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX9805512A (en) Treatment and prevention of cardiac insulin resistance associated conditions.
WO2001041754A3 (en) Inhibitors of collagen-induced platelet aggregation
Gillen et al. Problems associated with the clinical use of proton pump inhibitors
YU1203A (en) Treatment and prevention of cardiac insulin resistance associated conditions
AU2000258410A1 (en) New method for the preparation of the anti-ulcer compounds omeprazole, lansoprazole and pantoprazole
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2004043229A3 (en) Compounds for the treatment of tobacco dependence and withdrawal
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
WO2008051902A3 (en) Method of restoring the incretin effect
WO2009073146A3 (en) Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
WO2005016269A3 (en) Methods for treating metabolic syndrome
WO2006021654A8 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof
WO2004084874A3 (en) Mtp inhibitors for inhibiting inflammation